These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30642048)

  • 21. Development of an immunodetection test for a botulinum-like neurotoxin produced by Clostridium sp. RKD.
    Dixit A; Alam SI; Dhaked RK; Singh L
    Indian J Med Res; 2006 Sep; 124(3):355-62. PubMed ID: 17085839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of a stability-indicating RP-LC method for the assessment of recombinant human interleukin-11 and its correlation with bioassay.
    Souto RB; Stamm FP; Ribela MT; Bartolini P; Calegari GZ; Dalmora SL
    Anal Sci; 2012; 28(3):215-20. PubMed ID: 22451359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
    Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
    Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Replacement of the Mouse LD
    Fonfria E; Marks E; Foulkes LM; Schofield R; Higazi D; Coward S; Kippen A
    Toxins (Basel); 2023 Apr; 15(5):. PubMed ID: 37235349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.
    Roger Aoki K
    Toxicon; 2002 Jul; 40(7):923-8. PubMed ID: 12076646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A.
    Lawrence I; Moy R
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S66-71. PubMed ID: 19945007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioluminescence assay for the highly sensitive detection of botulinum neurotoxin A activity.
    Stevens GB; Silver DA; Zgaga-Griesz A; Bessler WG; Vashist SK; Patel P; Achazi K; Strotmeier J; Worbs S; Dorner MB; Dorner BG; Pauly D; Rummel A; Urban GA; Krueger M
    Analyst; 2013 Oct; 138(20):6154-62. PubMed ID: 23971072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A microscale neuron and Schwann cell coculture model for increasing detection sensitivity of botulinum neurotoxin type A.
    Hong WS; Young EW; Tepp WH; Johnson EA; Beebe DJ
    Toxicol Sci; 2013 Jul; 134(1):64-72. PubMed ID: 23564642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.
    Aoki KR
    Toxicon; 2001 Dec; 39(12):1815-20. PubMed ID: 11600142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of highly sensitive chemiluminescence enzyme immunoassay based on the anti-recombinant H(C) subunit of botulinum neurotoxin type A monoclonal antibodies.
    Liu Z; Song C; Li Y; Liu F; Zhang K; Sun Y; Li H; Wei Y; Xu Z; Zhang C; Yang A; Xu Z; Yang K; Jin B
    Anal Chim Acta; 2012 Jul; 735():23-30. PubMed ID: 22713913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved bioassays using a local effect, such as muscle paralysis, as an endpoint.
    Cevc G
    Toxicon; 2015 Jun; 99():89-94. PubMed ID: 25804992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism.
    Jones RGA; Marks JD
    J Med Microbiol; 2013 Jun; 62(Pt 6):828-835. PubMed ID: 23518650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a Highly Sensitive Cell-Based Assay for Detecting Botulinum Neurotoxin Type A through Neural Culture Media Optimization.
    Hong WS; Pezzi HM; Schuster AR; Berry SM; Sung KE; Beebe DJ
    J Biomol Screen; 2016 Jan; 21(1):65-73. PubMed ID: 26420788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aerobic growth and toxigenicity of Clostridium botulinum types A and B.
    Dezfulian M
    Folia Microbiol (Praha); 1999; 44(2):167-70. PubMed ID: 10588051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.
    Broide RS; Rubino J; Nicholson GS; Ardila MC; Brown MS; Aoki KR; Francis J
    Toxicon; 2013 Sep; 71():18-24. PubMed ID: 23707612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of biologically active botulinum neurotoxin--A in serum using high-throughput FRET-assay.
    Joshi SG
    J Pharmacol Toxicol Methods; 2012 Jan; 65(1):8-12. PubMed ID: 22178409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid method for purification of Clostridium botulinum type C neurotoxin by high performance liquid chromatography (HPLC).
    Matsuda M; Ozutsumi K; Du PY; Sugimoto N
    Eur J Epidemiol; 1986 Dec; 2(4):265-71. PubMed ID: 3542554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated bioassays in microfluidic devices: botulinum toxin assays.
    Mangru S; Bentz BL; Davis TJ; Desai N; Stabile PJ; Schmidt JJ; Millard CB; Bavari S; Kodukula K
    J Biomol Screen; 2005 Dec; 10(8):788-94. PubMed ID: 16234350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative duplex PCR of Clostridium botulinum types A and B neurotoxin genes.
    Kasai Y; Kimura B; Tajima Y; Fujii T
    Shokuhin Eiseigaku Zasshi; 2007 Feb; 48(1):19-26. PubMed ID: 17370613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum neurotoxin dose-dependently inhibits release of neurosecretory vesicle-targeted luciferase from neuronal cells.
    Pathe-Neuschäfer-Rube A; Neuschäfer-Rube F; Genz L; Püschel GP
    ALTEX; 2015; 32(4):297-306. PubMed ID: 26389683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.